A Bizarre Bacterial Defense

Nearly ten years ago, biochemist Ryan Jackson at Utah State University set out to understand how a newly discovered CRISPR protein called Cas12a2 worked. Assay after assay failed. "I accused my students of contaminating the protein," Jackson recalls.

The reason soon became clear: Cas12a2 was unlike any CRISPR enzyme known. When it recognized a matching RNA sequence, it didn't make a precise cut — it went wild, indiscriminately shredding the cell's DNA. In nature, bacteria use this as a kamikaze defense: when infected, the enzyme destroys the cell's genome entirely, stopping the infection from spreading.

Now, two independent teams of researchers have harnessed this destructive power for an entirely new purpose: fighting cancer.

Programmable Chemotherapy

In two landmark papers published in Nature on July 24, 2026, scientists demonstrated that Cas12a2 can be programmed to recognize specific messenger RNA molecules produced by cancer cells. Once the enzyme finds its target, it shreds the cancer cell's genome, causing the cell to self-destruct.

"It's a molecular kill switch that recognizes a particular RNA," says Yang Liu, a molecular biologist at the University of Utah School of Medicine and author of one of the papers. "This is basically a programmable chemotherapy."

One team targeted Cas12a2 towards cells with mutations in the TP53 gene, which is altered in up to half of all cancers. The other team targeted cancer cells driven by mutant KRAS proteins — some of the deadliest and most treatment-resistant forms of the disease.

Toward Human Trials

Akribion Therapeutics, a German biotechnology company in Zwingenberg, is already developing a therapy that uses this approach to target head and neck cancers caused by human papillomavirus (HPV). The goal is to produce the first clinical-trial data by 2030.

"How the hell does nature come up with a trick like that?" says Rene Bernards, a cancer geneticist at the Netherlands Cancer Institute in Amsterdam. "But, whatever. We can make good use of it."

The technique is particularly promising for cancers driven by 'undruggable' mutant proteins that have resisted conventional medicines. Because the enzyme is guided by RNA rather than protein recognition, it can in principle be aimed at any genetic signature — opening a new front in precision oncology.

Sources